Solta Medical Buying Guide: Thermage, Fraxel, or Clear + Brilliant?

Ask five clinic owners whether Solta Medical is worth it, and you'll get five different answers. That's not because the devices are inconsistent. It's because the right choice depends on your patient mix, your market, and whether your team can hold a difficult downtime conversation.

I'm not a dermatologist. I'm the procurement manager at a four-location medical aesthetics group. I've managed our device and consumables budget for six years, reviewed fourteen vendor proposals, and tracked every Solta-related invoice in our procurement system. So I'll talk about these machines like a buyer: what you pay, what you can charge, and where the hidden costs actually live.

Here's the honest version: there is no one-size-fits-all Solta Medical device. There are three scenarios where Thermage, Fraxel, or Clear + Brilliant is the right first purchase. And there's a fourth scenario where you shouldn't buy anything yet.

The Solta Stack in Plain English

Solta Medical is part of the Bausch Health portfolio. It was acquired by Valeant, now Bausch Health, in 2014. The three platforms you'll hear about are:

• Thermage - non-invasive facial skin tightening using monopolar radiofrequency. It's a one-treatment conversation, not a series.
• Fraxel - a fractional non-ablative laser for resurfacing. Texture, tone, melasma, mild acne scars.
• Clear + Brilliant - a lighter fractional laser used for prevention and maintenance. It's the 'lunch break glow' treatment.

What was best practice in 2020 may not apply in 2025. The fundamentals haven't changed: heat, fractional injury, collagen. But the execution and the service-contract terms have transformed significantly.

Wait, 'Solta Medical Stock'? Let's Clear That Up First

If you searched for Solta Medical stock, you're probably not looking for a ticker. In 2014, Solta Medical became part of Valeant Pharmaceuticals, which later renamed itself Bausch Health. So there's no direct Solta Medical stock to buy. The parent company trades as Bausch Health under BHC on the NYSE and TSX.

Why does that matter for a clinic purchase? Because device support depends on the company's staying power. According to Bausch Health's 2024 10-K, Solta Medical is still listed as part of its dermatology portfolio. That tells me the brand has corporate backing, which matters when you're negotiating a five-year service contract.

I'm not a financial advisor, so I won't tell you whether BHC is a good investment. From a procurement standpoint, what I can tell you is this: the company isn't a small startup that might disappear and leave you with an unsupported laser.

Scenario A: Your Patients Ask About 'Skin Tightening' Every Day

If your clinic is known for non-surgical facial rejuvenation and you see a lot of patients aged 45+, Thermage is the anchor device. It's the 'lift without a knife' conversation, and it's still one of the most recognizable names in facial skin tightening.

But there's a cost trap hiding in the business model. Thermage uses single-use, branded tips. The console price isn't the real cost; the per-treatment tip is. In Q3 2024, I reviewed Solta quotes from three distributors, and the five-year service-contract range was more than $17,000. That's not an argument against Thermage. It's an argument for pricing the entire treatment package properly before you sign.

One more thing: don't let 'non-invasive' turn into 'no pain management.' Thermage heats deep layers, and some patients find it uncomfortable. If you under-price the time and the numbing process, the case won't pay for itself.

Scenario B: Your Practice Treats Texture, Tone, and Melasma Cases

Fraxel is the stronger fit. It's a fractional non-ablative laser, which means it treats a fraction of the skin and leaves surrounding tissue intact. Recovery is more than a lunch break, but it's nowhere near old-school ablative downtime.

How long after Fraxel to see results? Here's the timeline I give every owner and every patient:

• Days 1-2: Redness and a sandpaper-like texture. Normal.
• Days 3-5: A bronze or dusky look. This is the stage where panicked patients send photos. Tell them to wait.
• Days 5-7: Flaking, followed by smoother-looking skin.
• Weeks 3-4: Pigment-related grid marks fade and tone starts to improve.
• Months 2-3: Collagen remodeling becomes visible. This is when most patients decide whether they'll book the next session.
• Months 4-6: Final result after a full package. Usually 3-4 sessions spaced 4-6 weeks apart.

From a P&L perspective, Fraxel has one advantage over Thermage: it creates a treatment series. Thermage is often a one-and-done service with a long interval between revisits. Fraxel forces a package conversation, and packages drive recurring revenue. That matters if your clinic depends on predictable monthly cash flow.

The downside is the capital and training cost. Don't buy a Fraxel system if your clinical director hasn't overseen a fractional-laser recovery process before. The machine itself won't produce good outcomes; the patient management around it will.

Scenario C: You're a Medical Spa Wanting a Low-Risk Entry Point

Clear + Brilliant is the device I'd start with. It's often the first laser a med spa buys because it has a recognizable brand name, Solta Medical Clear + Brilliant, plus lower per-treatment pricing and a subtle glow patients can see immediately.

Now, the 'Clear + Brilliant Permea' question. When you look that up, you're asking about the variation of the protocol that adds a permeability-enhancing step to deliver skincare actives more effectively. We tested it on patients whose main complaint was 'I use good products, but they're not doing anything.' The combined protocol did make a difference for that group. It also added appointment time and a per-case consumable that isn't on the standard C+B price sheet.

Is Permea worth it? It depends on your client's problem. If your clients are mostly prevention and maintenance, classic C+B is enough. If you're competing against another med spa that sells the science-heavy version, Permea can be a differentiator. Just make sure you're charging for it. It is not a free add-on, and pretending it is will quietly reduce your margin on every single case.

Scenario D (The One Most People Skip): Don't Buy Yet

This is the contrarian advice, and I'll keep it short. A lot of clinic owners finance a big device and then discover they're doing four treatments a week. In 2023, I went back and forth between buying a second Fraxel and leasing a unit through a distribution partner. On paper, buying made sense. But my gut said our volume wasn't reliable enough yet. Leasing cost more per treatment, but it didn't consume our credit line or leave us with a $100k machine collecting dust.

If you're a startup, or if your clinic can't guarantee at least 15 treatment hours per week for a new device, look at lease options or a revenue-share arrangement first. The goal is to prove the patient demand before you carry the full weight of the asset.

How to Determine Which Scenario You're In

Your patients will tell you if you listen. But if you need a framework, use ours:

• If the primary complaint is sagging, jawline, or facial skin tightening, start with Thermage.
• If the primary complaint is texture, scarring, melasma, or pigment, start with Fraxel.
• If the primary complaint is 'I want to look better without anyone knowing I had anything done,' start with Clear + Brilliant.
• If your current scheduling grid doesn't have room for a new service, don't buy any of them yet.

One honest caveat: this worked for us because we have four locations and a physician on staff. If you're a solo medical spa without medical oversight, the calculus is different. I can only speak to the procurement side; your clinical provider should approve every protocol before you spend a dollar.

The Bottom Line

Solta Medical isn't one product. It's a toolkit. Thermage is the high-ticket tightening conversation. Fraxel is the multi-session resurfacing engine. Clear + Brilliant is the front door that builds trust. Which one you need depends on the patient problem you're solving. If you don't know that yet, the answer isn't 'buy the biggest machine.' It's 'solve the problem, then choose.'

Trust me on this one. I learned the hard way when I assumed a system quote included the latest handpiece. It didn't. The upgrade was another $26,000, and the invoice taught me to verify every single line item before committing. The device is not the asset. The protocol and the pricing around it are.

I'm not a physician and not a securities analyst. Device claims and indications should be verified with your local Solta Medical representative and current FDA clearance documentation.